Figure 3From: Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program Progression-free and overall survival according to maintenance after 6 cycles. No maintenance- treatment interruption after 6 cycles (blue); maintenance- treatment beyond 6 cycles (green). Log-rank p-value for PFS, p = 0,007; Log-rank for OS, p = 0,0002.Back to article page